VivoSeq
Other

Endometrial Polyp

4

Pipeline Programs

1

Active Trials

3

Companies Involved

Endometrial Polyp is an early-stage landscape with 4 programs across 3 companies. The most active players are Pfizer, Ferring, Solvay Pharmaceuticals. 1 therapy is approved with 2 more in late-stage development.

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

75/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Trial Status

4

clinical trials

Completed2 · 50%
Unknown status1 · 25%
Not yet recruiting1 · 25%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)